Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non–small cell lung cancer
KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical cancer …, 2006 - AACR
Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
A phase I trial of targeted COX-2 and EGFR TK inhibition in advanced NSCLC
KL Reckamp, SM Dubinett, K Krysan… - Journal of Clinical …, 2005 - ascopubs.org
7112 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI)
is a novel targeted therapy for selected pts with NSCLC. Cyclooxygenase-2 (COX-2) is …
is a novel targeted therapy for selected pts with NSCLC. Cyclooxygenase-2 (COX-2) is …
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study
U Gatzemeier, A Ardizzoni, K Horwood… - Journal of Clinical …, 2007 - ascopubs.org
7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …
prolonged survival, delayed symptom progression, and improved quality of life versus …
[HTML][HTML] A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
[HTML][HTML] Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and …
KL Reckamp, BK Gardner, RA Figlin, D Elashoff… - Journal of Thoracic …, 2008 - Elsevier
Introduction Cyclooxygenase-2 overexpression may mediate resistance to epidermal growth
factor receptor tyrosine kinase inhibition through prostaglandin E2-dependent promotion of …
factor receptor tyrosine kinase inhibition through prostaglandin E2-dependent promotion of …
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non–small cell lung cancer patients …
Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
[HTML][HTML] Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer
YX Li, J Le Wang, M Gao, H Tang, R Gui… - American Journal of …, 2016 - ncbi.nlm.nih.gov
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …
due to the anticipation that it may be more effective than single drug treatment. In addition …